The Margin Wall That Revenue Couldn't Climb
CERA posted its strongest topline growth in years — +23.6% YoY — but net profit barely budged. Input cost inflation ate every rupee, and management's margin guidance missed by 130 basis points. The question now is whether H2 price hikes can deliver what Q2 couldn't.
₹603 Cr
+23.6% YoY, +24.1% QoQ
12.2%
−200 bps YoY, misses 13.5-14% guidance
₹56.1 Cr
−0.9% YoY flat, +23.9% QoQ
+16.6%
Core retail demand, despite price
The headline reads as a blowout — revenue up ₹23.6% YoY, volumes up 16.6%, faucetware surging +38%, sanitaryware steady at +24%. But scroll to the bottom line: PAT is down 0.9% year-on-year. On ₹603 crore of topline growth, CERA added almost no profit. That is the story of Q2: a company running harder and getting nowhere.
Where the margin went
Operating margin compressed from 14.2% a year ago to 12.2% — a 200 basis point cliff. Management's prior guidance had set a range of 13.5%–14%; the delivered 12.2% represents a miss of 130–250 bps depending on which edge you compare against. Input cost inflation is the culprit. Brass cost up 12% YoY. Gas — at 11–12% of sanitaryware COGS — up 40%. Freight surged 35–50%. Outsourcing partners, who account for 55% of production, carry thin margins and cannot absorb inflation; they pass cost straight to CERA.
Management took pricing action: 12% on sanitaryware in May, another 16% total on faucets by September. But those benefits will not materialize until new orders execute — Q3 and Q4. Q2 captured only a partial lift. As CFO Deepak Chaudhary put it, 'reversals have already been initiated' and the impact will become visible in the second half. That is not a guarantee; it is a road to be walked.
Revenue growth of 27.4% YoY
Delivered result: 23.6% YoY
Overstated
Strong growth trajectory with volume +16.6%, price +9.1%, mix +1.7%
Supported across all three levers; volumes genuinely strong despite price hikes
Supported
EBITDA margin 13.5–14% for FY27 (guidance from Q1 call)
Q2 delivered 12.2% OPM; FY27 target now revised to 13–14% (lower bound cut 50 bps)
Missed (margin guidance reset downward)
Confident of H2 margin recovery via price realization and cost actions
Price hikes taken, but flow-through in Q3–Q4 unproven; cost actions (automation, in-house shift) ongoing but no concrete $m benefit yet
Partially evidenced, execution risk remains
FY27 revenue growth to surpass 18–20% prior guidance
H1 +23.7%, Q2 +23.6% supports trajectory to exceed 20% for full year
Supported
What changed on this call
Revenue growth: raised to surpass 18–20% (from target to beat 18–20%)
EBITDA margin FY27: cut to 13–14% from 13.5–14%
Capex: H1 ₹27 Cr of ₹43 Cr full-year plan; timing under review for greenfield sanitaryware project
Project-retail mix: stabilizing toward 40–60% (projects–retail); currently 39–61%
FY28 guidance: deferred until end of FY27 (too early given macro uncertainty)
The bull-bear ledger
Volume growth +16.6% is real and strong; retail demand is recovering, not just project-driven
Sanitaryware and faucetware both growing; portfolio diversification working
In-house manufacturing rising (41–55% depending on segment); sourcing advantages vs unorganized competitors
Working capital improved: inventory down 14 days YoY, receivables down 5 days; no cash crunch
Margin miss is 130–250 bps; needs Q3–Q4 to recover despite size of headwind
PAT flat YoY despite 23.6% revenue growth; growth is not translating to earnings
Price hike benefits unproven; if demand softens or customers resist, realization lags further
Macro uncertainty ('precarious' external environment) capping management's visibility and FY28 guidance
Input cost inflation (brass +12%, gas +40%) persists; limited relief visible
HighQ2 margin 12.2% vs guidance 13.5–14% proves inflation is real and severe. Outsourcing partners (55% of biz) pass costs in full. If inflation sustains, H2 recovery may not reach 13–14% target.
Price hike realization lag; benefits only flow Q3–Q4, not yet proven
HighMay +12% and Sept +16% price hikes are in the market, but full benefit requires new orders to execute at higher pricing. If customers order less or project backlogs clear at old pricing, margin benefit undershoots.
Margin guidance miss signals execution risk
MediumFY27 guidance (13.5–14% margin) set in Q1 call was reset downward (now 13–14%) within one quarter. Forecasting accuracy questioned; if H2 also misses revised target, credibility erodes further.
Macro weakness ('precarious' external environment, geopolitics) could soften demand
MediumConstruction / real estate demand is not assured. Volume growth of +16.6% is strong so far, but discretionary demand in construction could stall if capex softens or interest rates remain elevated.
Project order backlog at old pricing; mix drag until fully transitioned
LowOlder projects deliver at ~39% margin vs newer projects at higher pricing. Until backlog clears, margin recovery will be partial. Not a blocker but a timing headwind.
How the street is positioned
The market has rendered its verdict: bearish. CERA trades at ₹4,893 as of Nov 11, down 54.65% from its all-time high of ₹10,789.95. It sits 15% below its 200-day moving average (₹5,440.67) and 5% below its 50-day average (₹5,146.36), trading above only the 20-day SMA of ₹4,734. RSI of 51.4 signals neutral momentum — the stock is neither oversold nor overbought, just stuck. Volume is normal; there is no capitulation or panic, just steady neglect.
Valuation and drawdown context: A 54.65% drawdown from ATH is severe for a company delivering 23.6% revenue growth and a market-leading position in sanitaryware. Either the market has priced in a permanent margin reset (12% OPM is the new normal), or it is waiting for concrete proof of the H2 recovery before re-rating. The stock's position well below the 200-day MA suggests the latter — skepticism, not capitulation.
Ownership flows: FII ownership ticked up to 15.43% in Q2 (from 14.19% in Q4), a gain of 124 basis points. This is nibbling, not conviction buying — but it signals some value hunters are starting to circle. DII ownership held steady at 14.06% (down 12 bps QoQ from 14.18%), suggesting domestic institutions are not yet adding. Promoter ownership remains locked at 54.41%, providing a steady hand. The bulk/block activity in June 2026 showed Goldman Sachs buying and HDFC Life selling at ₹5,480 — well above current levels — suggesting rotation rather than long-term conviction from large funds at that price.
The market and the fundamentals are aligned on one point: wait and see. Revenue growth is real, but margin recovery is not yet evident. When it is — when Q3 numbers show price hikes flowing through and Q2's 12.2% OPM climbing back toward 13–14% — the re-rating will come. Until then, the stock will trade as a high-growth, low-conviction story.
1 · Q3 margin trajectory
Does OPM climb from Q2's 12.2% toward the 13–14% target? Price hike benefits should start flowing; watch for evidence in the P&L. If Q3 OPM is still sub-13%, the H2 recovery case weakens materially.
2 · Input cost stabilization
Brass, gas, and freight inflation are the villain. Any reprieve in commodity prices would help, but management must articulate whether cost pressures are moderating or if pricing will need to hold permanently.
3 · Project order flow and pricing
Project business is 39–40% of revenue. Watch for visibility on new project awards at higher pricing vs. old backlog burning off at lower pricing. A mix shift toward retail (higher margin, more recurring) or new projects at higher pricing would de-risk the margin story.
CERA remains a steady franchise — dominant market position, real volume growth, and disciplined management. But Q2 represents a step sideways, not forward: the margin compression erased the profit upside of 23.6% revenue growth. Management has a coherent H2 recovery thesis (price flow-through, cost actions, old project backlog clearing), but it is unproven. The market is right to wait.
This is not a collapse or a collapse-in-waiting. It is a quarter where growth did not translate to profit, and the company must now walk the walk. Hold for Q3 results; the number to track from here is operating margin — will it climb from 12.2% or stay pinned? That answer determines whether CERA's re-rating is a Q4 story or a 2027 conversation.
Cera Q2 FY27 standalone: revenue +23.6% YoY but PAT flat, margins miss 13.5-14% guide
PAT -0.9% YoY · revenue +23.58% · margins compressing
₹602.96 Cr
+23.58% YoY
₹56.14 Cr
-0.9% YoY
9.15%
-2.1pp YoY
₹43.52
Cera Sanitaryware's standalone revenue grew 23.6% YoY to ₹602.96 Cr in Q2 FY27, comfortably ahead of management's maintained 18-20% FY27 guidance band, but net profit was essentially flat YoY at ₹56.14 Cr (-0.9%) as margins compressed sharply. NPM fell to 9.15% from 11.23% a year ago (-208 bps) and OPM to 12.15% from 13.76% (-161 bps) — both short of the 13.5-14% EBITDA margin management reiterated on the last call. There is no formal Street consensus estimate specifically for this quarter available; broader FY27 full-year consensus (from brokerage trackers) has pencilled in 15-20% PAT growth, a bar the H1 FY27 run-rate (standalone PAT down ~1.7% YoY) is currently tracking well behind, so vsStreet is left unknown rather than inferred from a non-quarter-specific number.
Q2 FY-2027 vs prior quarters
The margin bridge sits squarely on input costs: combined material consumption and traded-goods purchases rose roughly 41% YoY to ₹361.0 Cr, well ahead of the 23.6% revenue growth, while other expenses climbed 18.7% YoY and employee benefits expense rose 10.7% YoY — consistent with the ₹18.3 Cr full-year wage headwind flagged at the last concall. Sequentially the picture is better: revenue (+24.1% QoQ) and PAT (+23.9% QoQ) grew roughly in step with each other, and OPM improved 202 bps QoQ from Q1 FY27's 10.13%, showing some within-year margin recovery even though the YoY comparison still lags guidance.
The stock went into the print at ₹4,638.6, down 8.3% over the past month of trading.
What the summary numbers don't show
EPS ₹43.52 (basic & diluted) versus ₹43.92 a year ago and ₹35.13 last quarter.
No exceptional items in the current or year-ago quarter, unlike FY26's full-year ₹7.81 Cr labour-code provision — reported and adjusted PAT are identical this quarter.
FY27 revenue growth 18-20%; EBITDA margins 13.5-14% (maintained). ₹43 Cr capex; ₹85 Cr brand spend. Wage cost headwind ₹18.3 Cr full-year.
— This quarter: missed
No management press release or post-result commentary was available in the context to cross-check against the Board's own framing; the filing itself only discloses the unaudited numbers and a limited-review report from Singhi & Co. with an unmodified opinion. The quarter's other corporate developments — Board approval of the results on 4th November, the scheduled Q2/H1 FY27 earnings call on 5th November, and re-appointments of the Chairman & Managing Director and an Independent Director — are governance items with no direct bearing on this quarter's numbers.
W1
H2 FY27 margin trajectory against the maintained 13.5-14% EBITDA guidance — OPM has now missed guidance for two straight quarters (10.1% Q1, 12.15% Q2).
W2
Employee cost growth versus the ₹18.3 Cr FY27 wage headwind flagged last concall — employee benefits expense rose 10.7% YoY this quarter.
W3
Whether the Nov 5, 2026 Q2/H1 FY27 earnings call clarifies the drivers behind the ~41% YoY jump in materials + traded-goods cost.
Standalone-only filing (no consolidated statement present). Figures converted from ₹ Lakhs. No exceptional items in current or year-ago quarter — FY26's ₹7.81 Cr labour-code exceptional item sat only in the full-year (31.03.2026) column, so reported PAT = adjusted PAT. DB year-ago-quarter revenue (₹487.91 Cr) runs ~3% above this filing's own restated Q2 FY26 comparative column (₹473.41 Cr, per Note 5 regrouping); YoY growth below uses the DB comparison figure per the comparison-context instructions — PAT YoY is unaffected since the DB and filing PAT figures match almost exactly (₹56.65 Cr vs ₹56.65 Cr).
Record growth masks margin pressure
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q2 margin missed 13.5-14% guidance (delivered 12.2%); FY27 revenue guidance raised (surpass 18-20%) but margin cut to 13%-14%. H2 recovery unproven.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 revenue growth (+23.6%) offset by margin compression to 12.2%, below prior guidance of 13.5-14%, and flat YoY PAT. Management confident in H2 recovery via price hikes (12-16% taken), but execution risk remains as benefits only materializing in Q3-Q4; cost inflation (brass +12%, gas +40%) continues headwind.
₹603 Cr
Revenue · +23.6% YoY₹56.1 Cr
Reported PAT · −0.9% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Earnings quality
What changed since the last call
Revenue growth guidance raised
UpgradeNow expects to surpass 18-20% FY27 growth target (prior was hit 18-20%). Q2 delivers 23.6% YoY, supporting trajectory.
EBITDA margin guidance cut
DowngradeFY27 target revised down from 13.5-14% to 13%-14% (lower bound cut 50 bps). Q2 delivered 12.2%, furthest miss to date.
Cost inflation severity recognized
DowngradeBrass +12% YoY, gas +40% YoY, freight +35-50%. Outsourcing partners passing full cost inflation; limited absorptive capacity.
Project-retail mix shift acknowledged
NewProject mix fell to 39% (from 43% in Q1). Expected long-term split 40%-60% projects-retail. Impacts pricing and margin profile.
The Q&A
Analysts pressed hard on margin miss (Ulkarsh Nopany, Amit Srivastava) and cost inflation (Resha Mehta). Management held ground with detailed breakdowns (brass +2.1% impact, transport +1.9%, discount -1.7% on margin), acknowledged lag in price hike realization, and deferred FY28 guidance (reasonable given macro uncertainty). Fair questions, thorough answers.
Revenue growth drivers — Amit Srivastava, 360 ONE Capital
AnsweredVolume +16.6%, price +9.1%, mix +1.7%. Volume driven by retail demand recovery and project momentum; price from baseline plus Sept faucet hike.
Market share vs new demand — Amit Srivastava, 360 ONE Capital
AnsweredImproved demand from market and distribution network strengthening in Uttar Pradesh, Bihar, Odisha, Chhattisgarh. Actual market expansion.
Margin miss explanation — Amit Srivastava, 360 ONE Capital
AnsweredBrass impact +2.1% headwind, transportation +1.9%, turnover reversal +3.8%, discount -1.7%, publicity -0.5%. One-time effects reversed.
Project margin and mix timing — Amit Srivastava, 360 ONE Capital
AnsweredYes, as retail demand has now started growing. Project business was previously propping up mix. Mix moving toward 40%-60% equilibrium.
Geopolitical impact — Shreyans Jain, 3A Capital Services
AnsweredDouble-edged: gas inflation exacerbated by geopolitics, creating cost pressure. But opportunity as unorganized players struggle; CERA's sourcing advantages help.
In-house manufacturing plans — Sagnik Sarkar, SKP Securities
AnsweredFaucetware: shifting higher, capacity up to 5 lakh/month. Sanitaryware: stable at ~41% in-house; outsourcing SKUs have higher margins.
FY28 guidance — Resha Mehta, GreenEdge Wealth
DodgedToo early. Need to see how entire FY27 pans out, manufacturing/outsourcing scale up, and external environment clarity before FY28 targets.
Price hike reversal risk — Resha Mehta, GreenEdge Wealth
AnsweredNo. Historically, prices don't fall even when input costs decline. Benefits will flow through. Discounts may increase in projects if demand falls, but not list price reversals.
Gross margin pressure detail — Ulkarsh Nopany, Anand Rathi
AnsweredGas is 11%-12% of COGS for sanitaryware. Transportation up substantially. Outsourcing partners at thin margins, can't absorb inflation; pass it on. 55% of business from outsourcing partners impacted.
Acquisitions strategy — Bhupesh Kawdia, ICICI Direct
AnsweredCash has no impact on cost inflation problem. M&A considered, but strategic fit matters more than opportunism. Ongoing evaluation of outsourcing partners and competitors.
Price hike timeline and impact — Karan Bhatelia, Amsec
AnsweredMay: 12% sanitaryware. Sept: 8% faucets (total 24% cumulatively). No further hikes planned for Q3. Benefits to flow Q3-Q4 as new orders execute.
Guidance
FY27 revenue growth to surpass 18-20%
HighPrior target 18-20%, now expects >20%. Q1-Q2 average 23.7%, on track. Growth predominantly volume-driven (16.6% in Q2).
FY27 EBITDA margin 13%-14%
MediumRevised down from 13.5-14% due to input cost inflation. Q2 delivered 12.2%; need 14%+ in H2 to hit range. Price benefits Q3-Q4.
FY27 capex ~₹43 Cr
MediumH1 capex ₹27 Cr incurred. Faucetware brownfield expansion, sanitaryware greenfield project pending. Timing of greenfield affects H2 pace.
Risks the call surfaced
Input cost inflation
HighBrass +12% YoY, gas +40% YoY, freight +35-50%. Q2 margin 12.2% vs guidance 13.5-14%. Outsourcing partners can't absorb; pass full cost to CERA. Limited mitigation if inflation sustains.
Margin miss and Q2 guidance failure
HighDelivered Q2 OPM 12.2% fell short of prior 13.5-14% guidance, a 250-130 bps miss. Revised FY27 target now 13%-14%; need strong H2 to achieve. If price hikes don't flow through as expected or volumes soften, 13% floor at risk.
Price hike realization risk
MediumPrice hikes taken May (12% sanitaryware) and Sept (16% faucets total 24%). Benefits to flow Q3-Q4 as new/renewed orders execute at higher pricing. If demand weakens or customers resist, realization may lag.
Macro uncertainty and geopolitical risk
MediumManagement mentions 'precarious' external environment, 'uncertainties prevailing in the external market.' Geopolitical situation impacts input costs (gas) and potentially demand from construction/real estate.
Project mix concentration
LowProject business 39% of revenue. Old projects at lower margin (39%+) still delivering; new projects have higher pricing/margin. Mix shift risk if project momentum slows.
Management
Score 7/10. Clear and detailed. CFO provided specific breakdowns of margin drivers (brass +2.1%, transport +1.9%, etc.). Explained cost inflation comprehensively. Some hedging on FY28 guidance (reasonable given uncertainty). NDA shields on supplier/customer details but transparency on aggregate figures. Track record mixed. Q1 guidance (18-20% revenue, 13.5-14% margin) partially met: revenue tracking toward surpass, but margin missed (12.2% vs 13.5%+). Acknowledged miss and provided detailed drivers; credible reset to 13%-14% target.
1 · Q3 FY27 (Oct-Dec 2026)
Price hike benefits flow through; cost actions (automation, outsourcing shift) gain traction
2 · Q4 FY27 (Jan-Mar 2027)
Project order backlog at new pricing; margin recovery trajectory should become clear
3 · Mar 2027
FY27 full-year EBITDA margin outcome vs 13%-14% target; confirms/alters growth narrative
Management confident in H2 recovery via price hikes (12-16% taken), but execution risk remains as benefits only materializing in Q3-Q4; cost inflation (brass +12%, gas +40%) continues headwind.